Potentially lifesaving treatment for rare cancer patients that costs tens of thousands of dollars will be slashed to just $25 per round, pending federal government approval.
The cancer medication Keytruda is the world’s bestselling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of ...
Merck beats Q4 earnings on Keytruda strength, but 2026 guidance disappoints amid patent expirations and weaker Gardasil sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results